Global Tumor Ablation Therapy Devices Market

Point-of-care diagnostics devices are designed to aid doctors in performing medical diagnostic testing at or near the point of care, for immediate knowledge on diseases or conditions. These devices are used to test glucose and cholesterol levels, do electrolyte and enzyme analysis, test for drugs of abuse and for infectious diseases, and for pregnancy testing. The main types of point-of-care diagnostic devices and equipment are infectious disease testing kits, cardiometabolic monitoring kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, and others. Pregnancy and fertility test kits are point-of-care diagnostic devices used to test pregnancy and fertility prior to seeing a doctor. The various prescription modes include prescription-based testing devices, and over-the-counter (OTC) testing devices. These are used by end-users such as professional diagnostic centers, hospitals/critical care centres, outpatient healthcare settings, ambulatory care settings, research laboratories, and homes. The point-of-care diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides point-of-care diagnostics devices and equipment market statistics, including point-of-care diagnostics devices and equipment industry global market size, regional shares, competitors with a point-of-care diagnostics devices and equipment market share, detailed point-of-care diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care diagnostics devices and equipment industry. This point-of-care diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global point-of-care diagnostics devices and equipment market size will grow from $28.47 billion in 2022 to $32.34 billion in 2023 at a compound annual growth rate (CAGR) of 13.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global point-of-care diagnostics devices and equipment market size is expected to grow to $48.35 billion in 2027 at a CAGR of 10.6%. An increase in the incidence of target diseases is driving the POC devices and equipment market globally. The rising incidence of chronic diseases, like diabetes, rheumatism, or cancer is increasing steadily worldwide due to poor lifestyle choices and increasing obesity, thus driving the growth of the POC devices and equipment market. For example, according to the Centers for Disease Control and Prevention, In 2020, about 697,000 people in the US died due to heart disease. The POC diagnostics devices and equipment market is expected to slow down due to stringent regulatory policies, which increase the gestational period before the product enters the market. POC devices and equipment manufacturers are required to obtain multiple FDA clearances before launching their product into the market. The entire process of approval consumes a lot of time, thereby restraining the market growth. Over-the-Counter (OTC) testing is being termed as an important trend driving the growth of the point of care diagnostics market. FDA has approved OTC test kits for cholesterol, fecal occult blood, pregnancy, and HIV/HCV. This method would improve the access to testing and early detection of the disease. These testing kits may generate more revenue than prescription tests over the forecast period due to ease of using the kits, increased home care and self-testing, and a rise in availability and adoption rate. Point of care devices is regulated by the U.S. Food and Drug Administration (FDA) and all the diagnostic laboratory tests are regulated by the clinical laboratory improvement amendments of 1988 (CLIA) that are administered by the Centers for Medicare & Medicaid Services (CMS). As these devices measure the biomarker levels in the body they are classified as class II (requiring 510[k] approval), or III devices (requiring the more tedious premarket approval). On the contrary, to the stringent approvals by FDA, China has a moderately lenient approval mechanism. Therefore, the top companies are using a partnership approach with local vendors and distributors to expand their market share. Major players in the point-of-care diagnostic devices and equipment market are Abbott, F. Hoffmann-La Roche, Siemens Healthineers, Danaher, Beckman Coulter, Becton Dickinson and Company, QIAGEN N.V., Johnson & Johnson, Alere Inc., and BioMerieux. North America was the largest region in the point-of-care diagnostic devices and equipment market in 2022. Asia-Pacific was the second-largest region in the global point-of-care diagnostics devices and equipment market. The regions covered in global point-of-care diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the point-of-care diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The point-of-care diagnostics market consists of sales of instruments such as pregnancy and fertility testing kits, cholesterol test strips, drug abuse testing kits, and others that are used in point-of-care diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global point-of-care diagnostics devices and equipment market is segmented - 1) By Type: Infectious disease testing kits, Cardio metabolic monitoring kits,, Cholesterol testing kits, Pregnancy and fertility tests kits, Tumor/Cancer markers, Urinalysis testing kits, Hematology testing kits, Drugs of abuse testing kits, Fecal occult testing kits, Other Types 2) By End User: Professional diagnostic centers, Hospitals/critical care centers, Outpatient healthcare Setting, Ambulatory care settings, Research laboratories, Home 3) By Prescription Mode: Prescription-based Testing Devices, Over-The-Counter (OTC) Testing Devices

Psoriasis refers to a skin condition that typically affects the knees, elbows, trunk, and scalp and results with a rash with itchy, scaly spots. The primary contributing factor may be an immune system issue wherein infection-fighting cells unintentionally kill healthy skin cells. The main classes of drugs in psoriasis are interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different types of drugs include small molecules and biologics and involve various disease indications such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. The several routes of administration include oral, topical, injectable, and distributed through hospitals, retail pharmacies, and e-commerce. The psoriasis market research report is one of a series of new reports from The Business Research Company that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global psoriasis market size will grow from $20.31 billion in 2022 to $22.80 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global psoriasis market size is expected to grow to $34.50 billion in 2027 at a CAGR of 10.9%. The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to immune system, genetics, and environment. The rise in psoriasis patients in the past few years can be mainly attributed to climate change, stress, and an unhealthy lifestyle. According to the World Psoriasis Day consortium, 125 million people globally - 2 to 3 percent of the total population have psoriasis. Therefore, the rise in the prevalence of psoriasis patients is expected to propel the growth of the psoriasis over forecast period. The high cost of psoriasis therapy is expected to restrain the growth of the psoriasis market over the forecast period. For instance, according to a report published by WebMD, a US-based publication agency, disease-modifying antirheumatic medication (DMARD) used to treat PsA can cost between $1,500 and $2,000 per year. In the US, a dermatologist office visit typically costs $150 to $200. The high cost is because patent protections are preventing many alternative drugs. Therefore, the high cost of psoriasis therapy hampers the growth of the psoriasis market. Combination therapy is an emerging trend in the psoriasis market. Combination therapy is an f treatment that combines two different psoriasis treatments at the same time. When two drugs with different mechanisms of action are combined (combination therapy), the effect is greater than that obtained by monotherapy (treatment with a single drug). Studies suggest that combination therapy eases psoriasis symptoms more effectively than a single therapy and has lesser side effects. An example of combination therapy for the treatment of active psoriatic arthritis (PsA) is taltz (ixekizumab) with methotrexate developed by Eli Lilly and Company. The process of approval of psoriasis drugs is becoming easier globally. This is evident from the increasing approvals of drugs for psoriasis in recent years. Some of the examples include the first regulatory approval of SKYRIZI (risankizumab) for the treatment of plaque psoriasis in Japan, and the Center for Drug Evaluation and Research approved Avsola (infliximab-axxq) for the treatment of plaque psoriasis. Hence, the increasing ease of drug approvals is expected to drive the psoriasis drugs market in the forecast period. Major players in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co Inc. and Janssen Biotech. North America was the largest region in the psoriasis market in 2022. Middle East is expected to be the fastest-growing region in the global psoriasis market during the forecast period. The regions covered in the global psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global psoriasis market is segmented - 1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor 2) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce 3) By Drug Types: Small molecules, Biologics   4) By Route Of Administration: Oral, Tropical, Injectable 5) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell. The main types of antibody-drug conjugates are monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different products include Adcertis, Kadcyla, and others and involve various technologies such as immunogen technology, Seattle genetics technology, immunomedics technology, and others. It is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others, and is implemented in hospitals, clinics, and others. The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.. The global antibody drug conjugates market grew from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%. The antibody-drug conjugates market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market's growth. The challenges involved in the manufacturing of ADCs is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities necessitate a significant capital investment as well as extensive specialised training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibody manufacturing, such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates must be manufactured in aseptic environments, and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms. Manufacturers of antibody-drug conjugates are monitored by various regulatory bodies, such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance for the industry on ADC development, and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at the FDA, such as the Office of Biotechnology Products (OBP) and Office of Pharmaceutical Quality, primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). The small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for the review of the adequacy of the payload and linker, conjugation reactions, and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2022. The Middle East is expected to be the fastest growing region in the global antibody drug conjugates market during the forecast period. The regions covered in the global antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications 3) By Product: Adcertis, Kadcyla, Other Products 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology 5) By End User: Hospital, Clinics, Other End Users

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors, and they have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments for bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is a type of cancer that develops in the tissue that lines the inner surface of the bladder.There is no involvement of the bladder muscle. The different applications include low-grade tumors, and high-grade tumours and are distributed through various channels such as hospital pharmacies, retail pharmacies, and others. The bladder cancer drugs market research report is one of a series of new reports from The Business Research Company that provides bladder cancer drugs market statistics, including bladder cancer drugs industry global market size, regional shares, competitors with a bladder cancer drugs market share, detailed bladder cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the bladder cancer drugs industry. This bladder cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bladder cancer drugs market size will grow from $2.32 billion in 2022 to $2.66 billion in 2023 at a compound annual growth rate (CAGR) of 14.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bladder cancer drugs market size is expected to grow to $4.31 billion in 2027 at a CAGR of 12.9%. The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, an increase in smoking habits, and consuming water that contains Arsenic increase the chances of blood cancer. According to the American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market. The increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, the first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Major organizations are investing in the research to utilize nano-technology as a means to deliver drugs into the human body. Nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients because the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, the Center for Drug Research And Development in Canada pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology. The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there are subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments, a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for the time of tumor survival. Surrogate endpoints are used in clinical trials to save time and are especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration. The use of gene therapy is a key trend gaining popularity in the bladder cancer drug market. Gene therapy is a medical approach that treats or prevents disease by correcting the underlying genetic problem by altering a person's genetic makeup. For example, in December 2022, the US Food and Drug Administration (FDA), a federal agency of the Department of Health and Human Services in USA, approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. In August 2022, Merck & Co., a US-based pharmaceutical company, acquired Seagen for a deal amount of $40 billion. Through this acquisition, Merck & Co. expands its business in oncology. SeagenInc. is a US-based bio-technology company that develops various cancer drugs including bladder cancer drugs. Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International, and Johnson & Johnson. North America was the largest region in the bladder cancer drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global bladder cancer drugs market during the forecast period. The regions covered in the global bladder cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bladder cancer drugs refer to drugs or medications that are used in the treatment of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors, and they have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments for bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. The bladder cancer drugs market consists of sales of Atezolizumab, Avelumab, Balversa, and Bavencio. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bladder cancer drugs market is segmented - 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Brain tumor drugs refer to the drugs or medications that are used to treat brain tumor. Chemotherapy, hormone therapies, anticonvulsants, and painkillers are among the drugs used to treat brain tumours. While other prescription drugs are used to manage symptoms while the tumour is being treated, chemotherapy works to reduce or destroy brain tumours. The main types of drugs in brain tumors drugs are temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastomamultiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It’s one of a class of drugs called antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others (glioma, acoustic neuroma, meningioma) and are used in various sectors such as hospital pharmacies, clinics, and others. The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain tumor drugs market size will grow from $3.49 billion in 2022 to $3.74 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global brain tumor drugs market size is expected to grow to $4.74 billion in 2027 at a CAGR of 6.1%. The major driving factor responsible for the growth of the Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor is leading to a rise in the demand for the drugs used in their treatment. The increasing use of targeted therapies is acting as a restraint on the Brain Tumor drug market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that especially blocks cancer cells from growing and spreading. Similarly, Bevacizumab prevents the regeneration of cancer cells, unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period. Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment. The brain tumor market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The regulatory body requires the companies in the industry to adhere to the same rules for conducting clinical trials, consistently throughout the region. These rules are relating to the transparency of information and maintaining safety standards while conducting clinical trials of newly discovered drugs and therapies throughout the EU. The regulation also encourages cross-border cooperation for making the scope of these clinical tests wider. In December 2021, Sanofi, a France-based pharmaceutical company acquired Amunix Pharmaceuticals Inc. for a deal amount of $1 billion. Through this acquisition, Sanofi’s focus is on developing potentially transformative cancer therapies in immuno-oncology. Amunix Pharmaceuticals Inc. is a US-based pharmaceutical company that also includes brain tumor drugs. Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation and GE Healthcare. North America was the largest region in the brain tumor drugs market in 2022. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market during the forecast period. The regions covered in the global brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global brain tumor drugs market is segmented - 1) By Type: Medulloblastoma, Astrocytoma, Oligodendroglioma, Primitive Neuroectodermal (PNET), Others (Glioma, Acoustic Neuroma, Meningioma) 2) By Drugs: Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib 3) By End User: Hospital Pharmacies, Clinics, Other End-Users

The ovarian cancer drugs refer to cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in the ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others. The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, and sex cord-stromal tumor. The most frequent kind of ovarian cancer is epithelial ovarian cancer. The majority of ovarian tumors (90 percent) are epithelial. Ovarian cancer that began in the epithelial layer protecting the ovary is known as epithelial ovarian cancer. The different types of drugs include alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGF inhibitors, parp inhibitors, antineoplastics, others, and distribution channels such as hospital pharmacies, drug stores, others. The ovarian cancer drugs market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ovarian cancer drugs market size will grow from $3.20 billion in 2022 to $3.71 billion in 2023 at a compound annual growth rate (CAGR) of 16.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ovarian cancer drugs market size is expected to grow to $6.36 billion in 2027 at a CAGR of 14.4%. The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to the Cancer Statistics in 2020, published by the American Cancer Society, about 1,806,590 new cancer cases and 606,520 deaths were expected in the USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth. The increasing use of biologics and targeted therapies is restraining the Ovarian Cancer drug market growth. Targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroying normal cells. For example, Bevacizumab is a targeted therapy biologics drug used to treat Ovarian Cancer. A targeted therapy drug, Zejula was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in the drug pipeline. FDA has also approved Genentech’s biologics license for ovarian cancer drugs highlighting the fact many new companies are entering the biologics ovarian drug cancer market. Hence, the growing popularity of alternatives such as biologics and targeted therapies may hinder the growth of the ovarian cancer drugs market. Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consist of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions. The pharmaceutical companies in the ovarian cancer drugs market are investing in the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche's blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advanced stage (III or IV) ovarian cancer. The Ovarian cancer drugs market is governed by the regulatory framework of agencies such as the Food and Administration Agency (FDA) and the American Society of Clinical Oncology (ASCO). FDA's recommendation for the ovarian cancer drugs market in the form of guidelines is mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from subpart 'A' to subpart 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as kidney cancer. Subpart 'E' also includes guidelines for the monitoring and evaluation of clinical trials of ovarian cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in the ovarian cancer drugs industry are required to abide by the regulations under FDA. In September 2021, BoehringerIngelheim, a Germany-based biopharmaceutical company acquired Abexxa Biologics for an undisclosed amount. Through this acquisition, BoehringerIngelheim expands its portfolio in the field of oncology for treating cancer through Abexxa’s technology and antibody-based drugs. Abexxa Biologics is a biopharmaceutical company developing cancer drugs and immuno-oncology and oncology research for advanced precision medicines for cancer that includes all cancer types along with ovarian cancer drugs. Major players in the ovarian cancer drugs market are AstraZeneca, Roche, Tesaro, Clovis Oncology, BoehringerIngelheim, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb and Eli Lilly and Company. North America was the largest region in the ovarian cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market during the forecast period. The regions covered in the global ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ovarian cancer drugs market is segmented - 1) By Tumor Type: Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor 2) By Distribution Channel: Hospital Pharmacies, Drug Stores, Other Distribution Channels 3) By Drug Type: Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Other Drug Types

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer diagnostics market size will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cancer diagnostics market size is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd., GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2022. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

Interventional oncology devices are used in the diagnosis and treatment of cancer using minimally invasive techniques and advanced imaging technology. The main products of interventional oncology devices are embolization devices, ablation devices, and support devices. The embolization devices are intended for the embolization of the blood vessels of a variety of tumors. The interventional oncology devices are used to perform procedures such as thermal tumour ablation, non-thermal tumour ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE), or bland embolization, that are used to treat cancer types such as liver cancer, kidney cancer, lung cancer, bone cancer, and others. The interventional oncology devices market research report is one of a series of new reports from The Business Research Company that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional oncology devices market size will grow from $2.21 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional oncology devices market size is expected to grow from $3.03 billion in 2027 at a CAGR of 6.5%. The availability of private and government funding drove the interventional oncology devices market. In the field of cancer, funding from the government and private has increased, especially for the devices used in treatments as it promotes early detection and better survival rates. The American Cancer Society, the largest non-government, not-for-profit cancer research funder, has awarded 630 projects with a grant amount of $384,262,652 in 2021. BioProtect Ltd., an Israeli company that develops novel bioabsorbable polymer spacer balloons, received a funding of $13 million of its Series D equity financing from a leading global syndicate of venture investors that finances the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. Endosight, the first augmented-reality-guided ablative system, has received 20% of its funding from private organizations. The funding from government and private organizations helps in the development of new technologies and devices, thereby driving the interventional oncology devices market. Rising product recalls are likely to hinder the demand for interventional oncology devices. The number of interventional oncology product recalls has risen. For instance, in June 2020, the IceFORCE 2.1 CX Prostate Cryoablation Kit Visual ICE System of the Boston Scientific Corporation was recalled as the needle surface had deteriorated. In March 2020, Medtronic recalled the Pipeline Flex embolization system with Shield technology due to a fracture in the distal portion. These product recalls put financial strain on businesses and also hampers the demand, thus hindering the market. Companies are focusing on deploying robotics technology in interventional oncology devices, for higher efficiency. The robotic system integrates image-based planning and navigation with the installation of different instruments to the desired body part with better accuracy and efficiency. For instance, in March 2022, the U.S. Food and Drug Administration approved Quantum Surgical’s Epione interventional oncology robotics platform. In July 2020, Terumo Corporation, a Japanese medical device company, acquired Quirem Medical for $45 million. Through this acquisition, Terumo intends to launch the Holmium platform globally as a part of the ongoing expansion of its interventional oncology (IO) portfolio. It further strengthens the brand and extends manufacturing and clinical development activities. Quirem Medical is a Netherlands-based medical device company that develops and markets Holmium-166-based radioactive microspheres for Selective Internal Radiation Therapy (SIRT). Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Merit Medical Systems Inc., Philips Volcano, AngioDynamics Inc., GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated. North America was the largest region in the interventional oncology devices market in 2022. Asia-Pacific was the second largest region in the global interventional oncology devices market report. The regions covered in the global interventional oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional oncology devices market is segmented - 1) By Product: Embolization Devices, Ablation Devices, Support Devices 2) By Procedure: Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), Transcatheter Arterial Embolization (TAE) or Bland Embolization 3) By Cancer Type: Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer, Other Cancer Types